Your trusted destination for CME, CPD & Medical Education across the Middle East.
Tawam Hospital (SEHA / M42 Healthcare) & College of Medicine and Health Sciences, United Arab Emirates University
Dr. Aydah Al Awadhi is a premier Emirati consultant medical oncologist, clinical researcher, and cancer control strategist who has played a transformational role in elevating oncological care, cancer screening frameworks, and precision medicine standards across the United Arab Emirates. She earned her Doctor of Medicine (MD) degree with distinguished honors, followed by comprehensive postgraduate residency training in internal medicine. Driven to master the complex cellular and genetic mechanisms of malignant diseases, she completed subspecialty clinical fellowship training in medical oncology and hematology, earning a Master of Science (MSc) and Fellowship with the Royal College of Physicians (FRCP).
Practicing as Head of the Medical Oncology Department at Tawam Hospital—the regional center of excellence for cancer care in Al Ain operated by SEHA and M42 Healthcare—Dr. Al Awadhi directs high-acuity diagnostic and therapeutic pathways for solid tumors. Her specialized clinical scope encompasses breast cancer, gastrointestinal malignancies, lung cancer, gynecological oncology, targeted immunotherapies, and complex multi-modal cancer care protocols tailored to Middle Eastern patient populations.
Throughout her clinical tenure at Tawam Hospital, Dr. Al Awadhi has been a pivotal force in embedding oncology care within the broader national non-communicable disease (NCD) framework. Recognizing that early detection remains the single most effective intervention to reduce cancer-related mortality, she collaborates closely with public health authorities to establish standardized, population-wide screening guidelines for breast, colorectal, and cervical cancers across Abu Dhabi and the wider Emirates.
A major milestone of Dr. Al Awadhi’s clinical leadership has been introducing next-generation sequencing (NGS) and biomarker-driven targeted therapies into routine oncology care. Under her direction, multi-disciplinary tumor boards incorporate comprehensive genomic profiling to match cancer patients with personalized immunotherapies and targeted agents, significantly improving therapeutic response rates while minimizing systemic toxicities.
In addition to her departmental directorship and clinical practice, Dr. Al Awadhi is an active academic educator and clinical assistant professor at United Arab Emirates University (UAEU). She actively trains medical oncology fellows,internal medicine residents, and medical students, directing accredited clinical oncology workshops, tumor board seminars, and evidence-based pharmacotherapy modules. Her teaching philosophy emphasizes integrating translational cancer genetics with compassionate, holistic patient communication.
Dr. Al Awadhi is an exceptionally prolific physician-scientist who has authored numerous peer-reviewed scientific studies, clinical registry reports, and treatment guidelines in high-impact international journals, including The Oncologist,Annals of Oncology, Breast Cancer Research and Treatment, and BMC Cancer. Her research portfolio focuses on characterizing genetic mutations unique to Arab cancer cohorts, evaluating real-world outcomes of immune checkpoint inhibitors, and identifying socio-cultural barriers to cancer screening uptake.
Beyond her hospital and university leadership, Dr. Al Awadhi actively serves on national cancer committees, international advisory boards, and regional oncology research taskforces. She frequently represents the UAE at major global summits—such as the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO)—advocating for expanded clinical trial infrastructure and equitable access to novel anti-cancer therapeutics across the MENA region.
At the First UAE National Congress on NCDs 2026, Dr. Aydah Al Awadhi stands out as a core scientific keynote presenter, session leader, and oncology policy lead. Uniting oncologists, primary care physicians, health economists, and public health strategists, she provides delegates with essential, evidence-based strategies to optimize cancer screening algorithms, adopt state-of-the-art precision therapies, and strengthen national NCD control frameworks nationwide.


Middle East Heart Academy (MEHA)
Middle East Heart Academy (MEHA)

WiredIN Events LLC
WiredIN Events LLC